ITC To Probe Chinese Co. After Kan. AG Warns Of IP Theft

Law360 (January 22, 2021, 10:14 PM EST) -- The U.S. International Trade Commission has agreed to investigate whether Wuhan Healthgen Biotechnology Corp. is infringing two patents owned by Ventria Bioscience Inc., a decision that came a little over a week after the Kansas attorney general cited concerns about "Chinese economic espionage" in one of several letters submitted to the commission.

The ITC agreed to launch the investigation on Jan. 15 over Ventria's bid to block Wuhan Healthgen from importing plant-derived rHSA, or recombinant human serum albumins. Plant-derived rHSA is a protein used to make immunotherapy and gene therapy drugs and vaccines, including the development of COVID-19 vaccines, according to...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!